PPAR ligands: Potential therapies for metabolic syndrome

被引：48

作者：

Akiyama T.E. ^{[1
]}

Meinke P.T. ^{[1
]}

Berger J.P. ^{[1
]}

机构：

[1] Merck Research Laboratories, Rahway, NJ 07065

来源：

Current Diabetes Reports | 2005年 / 5卷 / 1期

关键词：

Metabolic Syndrome; Rosiglitazone; Pioglitazone; Telmisartan; Troglitazone;

D O I：

10.1007/s11892-005-0067-3

中图分类号：

学科分类号：

摘要：

Metabolic syndrome (MS), a condition characterized by multiple related clinical disorders including insulin resistance, central obesity, hyperlipidemia, hypertension, and heart disease, is an increasingly prevalent disease in industrialized societies. The intense research interest in the peroxisome proliferator-activated receptors (PPARs), by both the pharmaceutical industry and academia, stems largely from the well-documented therapeutic actions of their synthetic agonists in alleviating several of the maladies associated with MS. This report focuses on the current understanding of the mechanisms of action of PPAR agents and their clinical use in the context of MS. Copyright © 2005 by Current Science Inc.

引用

页码：45 / 52

页数：7

共 73 条

[1]

Moller D.E., Kaufman K.D., Metabolic syndrome: A clinical and molecular perspective, Annu. Rev. Med., (2004)

[2]

Farmer J.A., Hypertension and the metabolic syndrome, Curr. Cardiol. Rep., 6, pp. 427-433, (2004)

[3]

Ford E.S., Giles W.H., Dietz W.H., Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey, JAMA, 287, pp. 356-359, (2002)

[4]

Berger J., Moller D.E., The mechanisms of action of PPARs, Annu. Rev. Med., 53, pp. 409-435, (2002)

[5]

Dreyer C., Krey G., Keller H., Et al., Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors, Cell, 68, pp. 879-887, (1992)

[6]

Spiegelman B.M., Hu E., Kim J.B., Brun R., PPAR gamma and the control of adipogenesis, Biochimie, 79, pp. 111-112, (1997)

[7]

Kliewer S.A., Umesono K., Noonan D.J., Et al., Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors, Nature, 358, pp. 771-774, (1992)

[8]

Keller H., Dreyer C., Medin J., Et al., Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers, Proc. Natl. Acad. Sci. U S A, 90, pp. 2160-2164, (1993)

[9]

Wahli W., Braissant O., Desvergne B., Peroxisome proliferator activated receptors: Transcriptional regulators of adipogenesis, lipid metabolism and more, Chem. Biol., 2, pp. 261-266, (1995)

[10]

Wysowski D.K., Armstrong G., Governale L., Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001, Diabetes Care, 26, pp. 1852-1855, (2003)

← 1 2 3 4 5 6 7 8 →